Stem cell factor and crescentic glomerulonephritis

doi:10.1016/S0272-6386(03)00026-X

American Journal of Kidney Diseases

Volume 41, Issue 4, April 2003, Pages 785-795

https://doi.org/10.1016/S0272-6386(03)00026-X Get rights and content

Abstract

Background: Numerous cells and cytokines have been implicated in the pathogenesis of crescentic glomerulonephritis (CGN). Recently, there has been growing awareness of the role of mast cells and their growth factor, stem cell factor (SCF), in the process of tissue inflammation and fibrosis. Methods: In this study, renal biopsy specimens from 28 patients with a histopathologic diagnosis of CGN were evaluated immunohistochemically for the presence of mast cells, SCF, and its receptor (c-kit). In addition, CD34⁺ hematopoietic cells, monocytes (CD68⁺ cells), and myofibroblasts (α-smooth muscle actin-positive [α-SMA⁺] cells) were counted. Renal biopsy specimens from cadaveric kidney donors and kidneys removed for hypernephroma (n = 6) served as controls. Point counting of positive immunostaining for SCF, α-SMA, and collagens III and IV was undertaken. Glomerular and interstitial fibrosis (IF) scores were determined. Results: Patients who developed progressive chronic kidney failure showed a significant increase in percentage of crescents, number of interstitial c-kit⁺ cells, and glomerular CD68⁺ cells compared with those with a favorable outcome. Analysis showed a significant elevation of tryptase⁺ mast cells in the interstitium of renal biopsy specimens of patients with CGN compared with controls. SCF and c-kit⁺ cells were found in glomeruli and interstitium, with occasional immunostaining of the crescent with SCF. Both glomerular and interstitial SCF immunostaining was significantly higher in biopsy specimens of patients compared with controls. Glomerular and interstitial SCF showed a significant positive correlation with 24-hour urinary protein level. There were a few CD34⁺ cells in both glomeruli and interstitium, but their numbers did not differ between patients and controls. Colocalization of CD34⁺ and c-kit⁺ was seen in some rounded interstitial and spindle-shaped cells. Number of interstitial mast cells proved to be a strong predictor of IF. Glomerular SCF correlated negatively with creatinine clearance and positively with glomerular CD68⁺ cells. Interstitial immunostainable SCF correlated positively with interstitial CD68⁺ cells and interstitial collagen III. On double antigen labeling, SCF was shown in the vicinity of α-SMA⁺ cells. Conclusion: These results show the potential involvement of mast cells and their growth factor SCF/c-kit in CGN.

Section snippets

Patients

Twenty-eight of 43 available patients in the database of the Sheffield Kidney Institute (1992 to 2000), Sheffield, UK, were selected for the purpose of this study. Patients were excluded from the study either because of insufficient biopsy material or their biopsy specimens did not contain at least 10 glomeruli/biopsy. For a patient to have CGN, at least 30% of the total number of glomeruli in the biopsy should show crescents. Causes of CGN are listed in Table 1. Also included in the study are

Results

Median follow-up period for all patients was 8.25 months (range, 0.5 to 24 months). Demographic data for patients are listed in Table 2. Dividing patients into two groups based on the reciprocal of serum creatinine against time slope did not show a significant difference in clinical, histological, or immunohistochemical parameters of progressors and nonprogressors. However, in view of the short follow-up of some patients and that others presented with severely impaired kidney function that did

Discussion

This study shows for the first time the significant upregulation of the mast cell growth factor (SCF) in kidneys of patients with CGN. In this study, we confirmed previous observations of the upregulation of SCF in human nephropathies and showed the distribution to be primarily tubular, but also glomerular and interstitial. Also, we noted the presence of SCF within crescents. Previous studies have shown that mast cells, rather than SCF, may have a role in rapidly progressive GN1, 2 because they

References (48)

A Pesci et al.
Mast cells in fibrotic lung disorders
Chest
(1993)
C.M Williams et al.
The diverse potential effector and immunoregulatory roles of mast cells in allergic disease
J Allergy Clin Immunol
(2000)
C.H Smith et al.
Mast cell number and phenotype in chronic idiopathic urticaria
J Allergy Clin Immunol
(1995)
I Esposito et al.
Mast cell distribution and activation in chronic pancreatitis
Hum Pathol
(2001)
R.B Colvin et al.
Basophils and mast cells in renal allograft rejection
Lancet
(1974)
T Ehara et al.
Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis
Kidney Int
(1998)
K Hiromura et al.
Tubulointerstitial mast cell infiltration in glomerulonephritis
Am J Kidney Dis
(1998)
T Tóth et al.
Increased density of interstitial mast cells in amyloid A renal amyloidosis
Mod Pathol
(2000)
M Artuc et al.
Mast cell-fibroblast interactionsHuman mast cells as source and inducers of fibroblast and epithelial growth factors
J Invest Dermatol
(2002)
H Vliagoftis et al.
The protooncogene c-kit and c-kit ligand in human disease
J Allergy Clin Immunol
(1997)

A.F El-Koraie et al.

Role of mast cells in the progression of chronic glomerulonephritides

Kidney Int

(2001)

Y Yonemura et al.

In vitro expansion of hematopoietic progenitors and maintenance of stem cellsComparison between FLT3/FLK-2 ligand and KIT ligand

Blood

(1997)

A.M El Nahas et al.

Role of growth hormone in the development of experimental renal scarring

Kidney Int

(1991)

T Hiragun et al.

A fibrogenic cytokine, platelet derived growth factor (PDGF), enhances mast cell growth indirectly via SCF- and fibroblast-dependent pathway

J Invest Dermatol

(1998)

A.S Kirshenbaum et al.

Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)

Blood

(1999)

S.D Lyman et al.

c-Kit ligand and Flt3 ligandStem/progenitor cell factors with overlapping yet distinct activities

Blood

(1998)

N Okumura et al.

Chemotactic and chemokinetic activities of stem cell factor on murine hematopoietic progenitor cells

Blood

(1996)

A.J Rees et al.

Crescentic glomerulonephritis

F Levi-Schaffer et al.

Mast cell role in fibrotic diseases

Isr J Med Sci

(1995)

S.T Holgate

The epidemic of allergy and asthma

Nature

(1999)

T Ambrust et al.

Mast cell distribution in human liver disease and experimental rat liver fibrosisIndications for mast cell participation in development of liver fibrosis

J Hepatol

(1997)

T Tóth et al.

Mast cells in rapidly progressive glomerulonephritis

J Am Soc Nephrol

(1999)

I.S.D Roberts et al.

Mast cellsThe forgotten cells of renal fibrosis

J Clin Pathol

(2000)

A Hatamochi et al.

Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin

Arch Dermatol Res

(1985)

Cited by (29)

Early prediction of renal graft function: Analysis of a multi-center, multi-level data set
2022, Current Research in Translational Medicine
Citation Excerpt :
Thus, there was a strong negative correlation of SCF serum levels with eGFR. An association between SCF and renal function has been observed repeatedly in other contexts [40–43]. Experiments in rat offer a potential cause, suggesting an association of SCF expression with renal fibrosis [44].
Long-term graft survival rates after renal transplantation are still poor. We aimed to build an early predictor of an established long-term outcomes marker, the estimated glomerular filtration rate (eGFR) one year post-transplant (eGFR-1y).
A large cohort of 376 patients was characterized for a multi-level bio-marker panel including gene expression, cytokines, metabolomics and antibody reactivity profiles. Almost one thousand samples from the pre-transplant and early post-transplant period were analysed and employed for machine learning-assisted prediction.
Pre-transplant data led to a prediction achieving a Pearson's correlation coefficient of r=0.38 between measured and predicted eGFR-1y. Two weeks post-transplant, the correlation was improved to r=0.63, and at the third month, to r=0.76. eGFR values were stable throughout the first post-transplant year. Several characteristics were predictive for eGFR, including age of donor and recipient, body mass index, HLA mismatch, cytomegalovirus mismatch and valganciclovir prophylaxis. Additionally, a subset of 19 nuclear magnetic resonance bins of the urine metabolome data was shown to have potential applications in non-invasive eGFR monitoring. Importantly, we identified the expression of the genes TMEM176B and HMMR as potential prognostic markers for changes in the eGFR after the second post-transplantation week.
Our multi-center, multi-level data set represents a milestone in the efforts to predict transplant outcome. While an acceptable predictive capacity was achieved, we are still far from predicting changes in the eGFR precisely. Additional studies employing further marker panels are needed to establish predictors of eGFR-1y for clinical application; herein, gene expression markers seem to hold the most promise.
Mast cells in renal inflammation and fibrosis: Lessons learnt from animal studies
2015, Molecular Immunology
Citation Excerpt :
SCF serum levels rose importantly in patients with end-stage renal failure or patients with anti-neutrophil cytoplasmic autoantibody (ANCA) – associated GN (Kitoh et al., 1998) and, each time, levels were positively correlated with renal dysfunction parameters (El-Koraie et al., 2001). In addition, some authors found increased local concentrations of SCF in the kidney with a marked upregulation in patients with chronic renal failure (El-Koraie et al., 2001; El Kossi and El Nahas, 2003). SCF was found both in tubular cells and interstitial infiltrating cells as well as in the interstitial space and correlated with the number of mast cells.
Mast cells are hematopoietic cells involved in inflammation and immunity and have been recognized also as important effector cells in kidney inflammation. In humans, only a few mast cells reside in kidneys constitutively but in progressive renal diseases their numbers increase substantially representing an essential part of the interstitial infiltrate of inflammatory cells. Recent data obtained in experimental animal models have emphasized a complex role of these cells and the mediators they release as they have been shown both to promote, but also to protect from disease and fibrosis development. Sometimes conflicting results have been reported in similar models suggesting a very narrow window between these activities depending on the pathophysiological context. Interestingly in mice, mast cell or mast cell mediator specific actions became also apparent in the absence of significant mast cell kidney infiltration supporting systemic or regional actions via draining lymph nodes or kidney capsules. Many of their activities rely on the capacity of mast cells to release, in a timely controlled manner, a wide range of inflammatory mediators, which can promote anti-inflammatory actions and repair activities that contribute to healing, but in some circumstances or in case of inappropriate regulation may also promote kidney disease.
Eosinophil activation of fibroblasts from chronic allergen-induced disease utilizes stem cell factor for phenotypic changes
2008, American Journal of Pathology
Citation Excerpt :
Evidence for a role of SCF in human airway disease was supported by studies demonstrating increased SCF expression in nasal polyps of asthmatics and allergic rhinitis patients.33,34 Additionally, SCF has been implicated as a potential mediator in fibrotic diseases in the kidney and intestine.34–37 Recently, the role of SCF has been verified using a chronic mouse model of allergic disease characterized by airway hyperresponsiveness, mucus overproduction, eosinophil accumulation, and peribronchial collagen deposition.11,13,14
In the present studies the role of stem cell factor (SCF) in mediating eosinophil and fibroblast activation during their interaction was investigated. SCF was significantly higher in fibroblasts grown from lungs of chronic allergen-challenged mice compared to fibroblasts grown from normal mice. When eosinophils were layered onto fibroblasts from allergic mice, a significant increase in SCF was detected compared to fibroblasts from nonallergic mice. The interaction of fibroblasts with eosinophils also increased the production of asthma-associated chemokines, CCL5 and CCL6, was dependent on cell-to-cell interaction, and was observed only with fibroblasts derived from lungs of chronic allergen-challenged mice and not from those derived from unchallenged normal mice. Chemokine production was significantly decreased when anti-SCF antibodies were added during eosinophil-fibroblast interaction. The interaction of fibroblasts from chronic allergen-challenged mice with eosinophils also increased α-smooth muscle cell actin and procollagen I expression as well as induced transforming growth factor-β. The changes in myofibroblast activation were dependent on SCF-mediated pathways because anti-SCF antibody treatment reduced the expression of all three of these latter fibrosis-associated markers. Thus, our data suggest that SCF mediates an important activation pathway for fibroblasts during chronic allergic responses on interaction with recruited eosinophils and suggest a potential mechanism of airway remodeling during chronic disease.
Mast cell, a promising therapeutic target in tubulointerstitial fibrosis
2007, Medical Hypotheses
Tubulointerstitial fibrosis is a final common pathway to the eventual structural desolation of kidneys. However, the mechanism involved in this phenomenon is still poorly understood, and current therapies are ineffective or only marginally effective. Mast cell has a variety of physiological and pathological functions through the production of heparin, histamine, neutrophil chemoattractants, immunoregulatory cytokines, and mast cell-specific serine proteases tryptase and chymase. The survival and proliferation of mast cell are dependent upon stem cell factor. Presently, mast cells are known to participate in the pathogenesis of tubulointerstitial fibrosis in many kidney diseases. Several therapeutic approaches to inhibit mast cell activation have already demonstrated some clinical utility in tissue fibrosis or inflammatory diseases such as the use of mast cell stabilizers, inhibitors of tryptase or chymase, blockade of stem cell factor and anti-IgE therapy. We hypothesize that mast cell has a significant role in the progression of tubulointerstitial fibrosis, thus the treatment strategies based on mast cell appear to be promising in these conditions. Development of these novel therapeutic approaches will enable us to target any types of renal disease.
Mesangial Proliferative Glomerulonephritis After Autologous Stem Cell Transplantation
2006, American Journal of Kidney Diseases
Although glomerulonephritis and renal failure have been observed after allogenic stem cell transplantation, only a few such reports were published about patients undergoing autologous stem cell transplantation. We report a case of mesangial proliferative glomerulonephritis developing 4 months after autologous stem cell transplantation for chronic lymphatic leukemia. Serological test results, together with histological, immunohistochemical, and electronic microscopic findings of a kidney biopsy specimen, confirmed the diagnosis of mesangial proliferative glomerulonephritis in our patient. Complement and immunoglobulin A were not present in the kidney biopsy specimen. An abnormal clone, not previously reported, with the translocation t(5;11)(q31;q13) in blood and bone marrow was observed. The reason for and whether progenitor cells in stem cell transplantations could contribute to the development of glomerulonephritis remain open questions. Kidney biopsy should be performed in patients with microscopic hematuria and/or proteinuria after autologous stem cell transplantation.
Plasticity of kidney cells: Role in kidney remodeling and scarring
2003, Kidney International
Citation Excerpt :
The source and nature of MAPCs remains a subject of controversy and debate. Preliminary data from our laboratory and that of others [67] have also implied a contribution by bone-marrow-derived mesenchymal cells (MSCs) to the renal interstitial fibroblastic pool. MSCs are marrow-derived progenitors of tissue fibroblasts and shuttle through the circulation between the marrow and peripheral organs [39].
Plasticity of kidney cells: Role in kidney remodeling and scarring. The progression of renal scarring and the associated loss of function remains one of the main challenges in nephrology. Until recently, the glomerular and tubulointerstitial scarring processes were thought to involve primarily interactions between infiltrating inflammatory cells and resident renal cells culminating in loss of renal cells and their replacement by extracellular collagenous matrix (ECM). This review focuses on new aspects of renal response to injury and remodeling. Emphasis is on the plasticity of renal cells with the capacity of both glomerular and tubular cells to assume a range of phenotypes during the remodeling process. Both glomerular and tubular epithelial cells regress to primitive/embryonic mesenchymal phenotype in response to injury. This reverse embryogenesis is a key step in renal healing and scarring. In addition to the plasticity of intrinsic renal cells, it is becoming apparent that renal remodeling in health and disease involves the migration of progenitor hematopoietic stem cells into the kidneys. These cells assume various glomerular and tubular epithelial phenotype. They are also involved in the evolution of lesions toward healing or scarring. A better understanding of some of these key events in renal remodeling and their mediators may open the way to new interventions based on their manipulations and aimed at favoring renal healing and preventing scarring.

View all citing articles on Scopus

View full text

Original investigation: pathogenesis and treatment of kidney disease and hypertensionStem cell factor and crescentic glomerulonephritis

Abstract

Section snippets

Patients

Results

Discussion

Chest

J Allergy Clin Immunol

J Allergy Clin Immunol

Hum Pathol

Lancet

Kidney Int

Am J Kidney Dis

Mod Pathol

J Invest Dermatol

J Allergy Clin Immunol

Kidney Int

Blood

Kidney Int

J Invest Dermatol

Blood

Blood

Blood

Crescentic glomerulonephritis

Mast cell role in fibrotic diseases

Isr J Med Sci

The epidemic of allergy and asthma

Nature

Mast cell distribution in human liver disease and experimental rat liver fibrosisIndications for mast cell participation in development of liver fibrosis

J Hepatol

Mast cells in rapidly progressive glomerulonephritis

J Am Soc Nephrol

Mast cellsThe forgotten cells of renal fibrosis

J Clin Pathol

Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin

Arch Dermatol Res

Original investigation: pathogenesis and treatment of kidney disease and hypertension
Stem cell factor and crescentic glomerulonephritis